SCHEMBL4367374

SCHEMBL4367374

CCCOc1ccccc1[C](c1ccccc1)c1ccccc1OCCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 3/20 0.50
HIF1A Q16665 1/20 0.50
LMNA P02545 5/20 0.47
MAPT P10636 2/20 0.47
NR1I2 O75469 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADRA2A P08913 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
ALDH1A1 P00352 6/20 0.46
PTK2B Q14289 1/20 0.46
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4362613 0.96 KMT2A (0.50) KMT2AMEN1HIF1ALMNAMAPT
SCHEMBL4366626 0.91 LMNA (0.54) KMT2AMEN1HIF1ALMNAMAPT
SCHEMBL2492279 0.89 LMNA (0.53) KMT2AMEN1HIF1ALMNAMAPT
SCHEMBL4365539 0.88 LMNA (0.54) KMT2AMEN1HIF1ALMNAMAPT
SCHEMBL4363572 0.85 MEN1 (0.56) KMT2AMEN1LMNAMAPTALDH1A1
SCHEMBL8142503 0.85 LMNA (0.63) KMT2AMEN1LMNAMAPTNR1I2
SCHEMBL5820347 0.85 LMNA (0.63) KMT2AMEN1LMNAMAPTNR1I2
SCHEMBL5820306 0.85 LMNA (0.63) KMT2AMEN1LMNAMAPTNR1I2
SCHEMBL30444952 0.83 DRD2 (0.61) KMT2AMEN1HIF1ALMNAMAPT
SCHEMBL5598745 0.83 DRD2 (0.61) KMT2AMEN1HIF1ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2749566-B1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE AIST (JP) 2018-05-09 EP disclosed
US-9428809-B2 Solid-phase carrier for aminated oligonucleotide NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2016-08-30 US disclosed
US-20140187724-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2014-07-03 US disclosed
EP-2749566-A1 SOLID-PHASE CARRIER FOR AMINATED OLIGONUCLEOTIDE National Institute of Advanced Industrial Science And Technology (JP) 2014-07-02 EP disclosed
EP-1908829-B1 OLIGONUCLEOTIDE PROBE NAT INST OF ADVANCED IND SCIEN (JP) 2014-01-08 EP disclosed
US-7491857-B2 Oligonucleotide probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-02-17 US disclosed
US-20080227968-A1 Oligonucleotide Probe NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2008-09-18 US disclosed
EP-1908829-A1 OLIGONUCLEOTIDE PROBE National Institute of Advanced Industrial Science and Technology (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227968-A1 Oligonucleotide Probe APEX1, RNGTT, RNASEH1 KMT2A 3173/4885MEN1 1946/4885HIF1A 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.